{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:57:20Z","timestamp":1793379440208,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bpg.2021.101757","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T18:37:16Z","timestamp":1623868636000},"page":"101757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Immunosuppressive drugs modes of action"],"prefix":"10.1016","volume":"54-55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-923X","authenticated-orcid":false,"given":"Maria","family":"Meneghini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Grinyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bpg.2021.101757_bib1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bpg.2021.101757_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1210\/er.2002-0006","article-title":"The interplay between the glucocorticoid receptor and nuclear factor-\u03baB or activator protein-1: molecular mechanisms for gene repression","volume":"24","author":"De Bosscher","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpg.2021.101757_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1513\/pats.200402-005MS","article-title":"Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells","volume":"1","author":"Necela","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.bpg.2021.101757_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids. Mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheumatic Disease Clinics of North America. W.B. Saunders"},{"key":"10.1016\/j.bpg.2021.101757_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.imbio.2009.10.003","article-title":"Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells","volume":"215","author":"Boldizsar","year":"2010","journal-title":"Immunobiology. Urban & Fischer"},{"key":"10.1016\/j.bpg.2021.101757_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00063030-199809010-00004","article-title":"Azathioprine: clinical pharmacology and current indications in autoimmune disorders","volume":"9","author":"Anstey","year":"1998","journal-title":"BioDrugs"},{"issue":"2\u20133","key":"10.1016\/j.bpg.2021.101757_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.bpg.2021.101757_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1358\/dot.2009.45.7.1384878","article-title":"Mycophenolate mofetil: an update","volume":"45","author":"Villarroel","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.bpg.2021.101757_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpg.2021.101757_bib10","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2165\/0003495-200868170-00007","article-title":"Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11938-017-0128-0","article-title":"Thiopurines and methotrexate use in IBD patients in a biologic Era","volume":"15","author":"Mantzaris","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2021.101757_bib12","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 Years Later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bpg.2021.101757_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.trre.2015.04.007","article-title":"Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients","volume":"29","author":"Shi","year":"2015","journal-title":"Transplantation Reviews. W.B. Saunders"},{"issue":"8","key":"10.1016\/j.bpg.2021.101757_bib14","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.transproceed.2009.08.043","article-title":"Inhibitory effects of cyclosporine on human regulatory T cells in vitro","volume":"41","author":"Miroux","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2021.101757_bib15","series-title":"Therapeutic drug monitoring. Ther drug monit","first-page":"429","article-title":"Clinical development of a cyclosporine microemulsion in transplantation","author":"Kovarik","year":"1996"},{"key":"10.1016\/j.bpg.2021.101757_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist","volume":"2","author":"Schiff","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101757_bib17","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI116440","article-title":"Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles","volume":"91","author":"Lanese","year":"1993","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep34845","article-title":"Bioprinting of 3D convoluted renal proximal tubules on perfusable chips","volume":"6","author":"Homan","year":"2016","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.bpg.2021.101757_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2021.101757_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1159\/000127432","article-title":"Prolonged endoplasmic reticulum stress induces apoptotic cell death in an experimental model of chronic cyclosporine nephropathy","volume":"28","author":"Han","year":"2008","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity\u2014what the FK?","volume":"27","author":"Farouk","year":"2020","journal-title":"Adv Chron Kidney Dis"},{"key":"10.1016\/j.bpg.2021.101757_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cpt.546","article-title":"Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus","volume":"101","author":"Chakkera","year":"2017","journal-title":"Clinical Pharmacology and Therapeutics. Nature Publishing Group"},{"key":"10.1016\/j.bpg.2021.101757_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2220","article-title":"Sustained inhibition of calcineurin activity with a melt-dose once-daily tacrolimus formulation in renal transplant recipients","author":"Fontova","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101757_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","article-title":"Roles of mTOR complexes in the kidney: implications for renal disease and transplantation","volume":"12","author":"Fantus","year":"2016","journal-title":"Nature Reviews Nephrology. Nature Publishing Group"},{"key":"10.1016\/j.bpg.2021.101757_bib25","first-page":"2","article-title":"Can mTOR inhibitors reduce the risk of late kidney allograft failure?","volume":"21","author":"Ponticelli","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.bpg.2021.101757_bib26","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.3389\/fimmu.2018.02953","article-title":"Selective effects of mTOR inhibitor Sirolimus on na\u00efve and CMV-specific T cells extending its applicable range beyond immunosuppression","volume":"9","author":"Bak","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.bpg.2021.101757_bib27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ctr.12559","article-title":"Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?","volume":"29","author":"Bhat","year":"2015","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/TP.0000000000000289","article-title":"Antithymocyte globulin facilitates alloreactive T-cell apoptosis by means of caspase-3: potential implications for monitoring rejection-free outcomes","volume":"99","author":"Ashok kumar","year":"2015","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.bpg.2021.101757_bib29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00007890-200102150-00021","article-title":"Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model","volume":"71","author":"Pr\u00e9ville","year":"2001","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.bpg.2021.101757_bib30","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/ndt\/gfu079","article-title":"The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients","volume":"29","author":"Bouvy","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2021.101757_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.tp.0000251975.81281.22","article-title":"Antithymocyte globulins suppress dendritic cell function by multiple mechanisms","volume":"83","author":"Naujokat","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trim.2012.11.008","article-title":"Retreatment by antithymocyte globulin for second kidney transplantation: Efficacy, tolerance and safety","volume":"28","author":"Rodr\u00edguez-Reimundes","year":"2013","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.bpg.2021.101757_bib33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-6143.2010.03400.x","article-title":"Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients","volume":"11","author":"Jordan","year":"2011","journal-title":"American Journal of Transplantation. Am J Transplant;"},{"issue":"3","key":"10.1016\/j.bpg.2021.101757_bib34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2017060679","article-title":"Control of humoral response in renal transplantation by Belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk","volume":"29","author":"Leibler","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bpg.2021.101757_bib35","first-page":"1440","article-title":"Belatacept in solid organ transplant: review of current literature across transplant types","volume":"102","author":"Perez","year":"2018","journal-title":"Transplantation. Lippincott Williams and Wilkins"},{"issue":"8","key":"10.1016\/j.bpg.2021.101757_bib36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/TP.0b013e3181d02496","article-title":"Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study","volume":"89","author":"Kandus","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2021.101757_bib37","doi-asserted-by":"crossref","DOI":"10.1385\/MO:19:2S:S03","article-title":"A personal history of the CAMPATH-1H antibody","volume":"19","author":"Waldmann","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.bpg.2021.101757_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOT.0b013e32832b45d0","article-title":"Alemtuzumab and liver transplantation: a review","volume":"14","author":"Dhesi","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.bpg.2021.101757_bib39","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2217\/fon.14.146","article-title":"Rituximab: modes of action, remaining dispute and future perspective","volume":"10","author":"Abulayha","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.bpg.2021.101757_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2018.02.030","article-title":"A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review","volume":"22","author":"Shahmohammadi","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.bpg.2021.101757_bib41","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3389\/fimmu.2021.661196","article-title":"The role of B cells and B cell therapies in immune-mediated liver diseases","volume":"12","author":"Cargill","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"issue":"8","key":"10.1016\/j.bpg.2021.101757_bib43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bpg.2021.101757_bib44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.dld.2006.10.017","article-title":"Treatment of life-threatening type I refractory coeliac disease with long-term infliximab","volume":"40","author":"Costantino","year":"2008","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10.1016\/j.bpg.2021.101757_bib45","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/gutjnl-2018-317977","article-title":"Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances","volume":"68","author":"Zundler","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101757_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/ITT.S282466","article-title":"All are equal, some are more equal: targeting IL 12 and 23 in ibd \u2013 a clinical perspective","volume":"9","author":"Jefremow","year":"2020","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.bpg.2021.101757_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:03:35Z","timestamp":1761498215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691821000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":47,"alternative-id":["S1521691821000378"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101757","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive drugs modes of action","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101757"}}